| Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models H Kim, E George, RL Ragland, S Rafail, R Zhang, C Krepler, MA Morgan, ... Clinical Cancer Research 23 (12), 3097-3108, 2017 | 253 | 2017 |
| Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial C Kunos, F Simpkins, H Gibbons, C Tian, H Homesley Obstetrics & Gynecology 114 (3), 537-546, 2009 | 218 | 2009 |
| Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models H Kim, H Xu, E George, D Hallberg, S Kumar, V Jagannathan, ... Nature communications 11 (1), 3726, 2020 | 211 | 2020 |
| Visual working memory in primary generalized epilepsy: An18 FDG-PET study BE Swartz, F Simpkins, E Halgren, M Mandelkern, C Brown, ... Neurology 47 (5), 1203-1212, 1996 | 182 | 1996 |
| Proteomic analysis for the early detection and rational treatment of cancer—realistic hope? EM Posadas, F Simpkins, LA Liotta, C MacDonald, EC Kohn Annals of oncology 16 (1), 16-22, 2005 | 162 | 2005 |
| BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer S Karakashev, H Zhu, Y Yokoyama, B Zhao, N Fatkhutdinov, ... Cell reports 21 (12), 3398-3405, 2017 | 161 | 2017 |
| A PET imaging agent for evaluating PARP-1 expression in ovarian cancer M Makvandi, A Pantel, L Schwartz, E Schubert, K Xu, CJ Hsieh, C Hou, ... The Journal of clinical investigation 128 (5), 2116-2126, 2018 | 119 | 2018 |
| Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer CD Capo-chichi, KQ Cai, F Simpkins, P Ganjei-Azar, AK Godwin, XX Xu BMC medicine 9, 1-12, 2011 | 111 | 2011 |
| Cortical metabolic activation in humans during a visual memory task BE Swartz, E Halgren, JM Fuster, F Simpkins, M Gee, M Mandelkern Cerebral Cortex 5 (3), 205-214, 1995 | 111 | 1995 |
| Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening F Simpkins, JL Belinson, PG Rose Gynecologic oncology 107 (1), 118-123, 2007 | 107 | 2007 |
| RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance Y Wang, JJ Krais, AJ Bernhardy, E Nicolas, KQ Cai, MI Harrell, HH Kim, ... The Journal of clinical investigation 126 (8), 3145-3157, 2016 | 92 | 2016 |
| Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin–epithelin precursor (GEP), a prosurvival … M Kamrava, F Simpkins, E Alejandro, C Michener, E Meltzer, EC Kohn Oncogene 24 (47), 7084-7093, 2005 | 88 | 2005 |
| Cisplatin resistance in human cervical, ovarian and lung cancer cells J Chen, C Solomides, H Parekh, F Simpkins, H Simpkins Cancer chemotherapy and pharmacology 75, 1217-1227, 2015 | 87 | 2015 |
| New insights on the role of hormonal therapy in ovarian cancer F Simpkins, A Garcia-Soto, J Slingerland Steroids 78 (6), 530-537, 2013 | 79 | 2013 |
| VEGFA activates an epigenetic pathway upregulating ovarian cancer‐initiating cells K Jang, M Kim, CA Gilbert, F Simpkins, TA Ince, JM Slingerland EMBO molecular medicine 9 (3), 304-318, 2017 | 71 | 2017 |
| A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers E George, H Kim, C Krepler, B Wenz, M Makvandi, JL Tanyi, E Brown, ... JCI insight 2 (1), 2017 | 70 | 2017 |
| Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells F Simpkins, K Jang, H Yoon, KE Hew, M Kim, DJ Azzam, J Sun, D Zhao, ... Clinical cancer research 24 (19), 4874-4886, 2018 | 67 | 2018 |
| SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics F Simpkins, JA Czechowicz, L Liotta, EC Kohn Future Medicine Ltd 6 (6), 647-653, 2005 | 64 | 2005 |
| Improved Sensitivity of 18FDG‐Positron Emission Tomography Scans in Frontal and “Frontal Plus” Epilepsy BE Swartz, A Khonsari, C Brown, M Mandelkern, F Simpkins, ... Epilepsia 36 (4), 388-395, 1995 | 64 | 1995 |
| Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer PD Shah, SL Wethington, C Pagan, N Latif, J Tanyi, LP Martin, M Morgan, ... Gynecologic oncology 163 (2), 246-253, 2021 | 61 | 2021 |
